Significance of Free to Total PSA Ratio in Men with Slightly Elevated Serum PSA Levels: A Cooperative Study

Japanese Journal of Clinical Oncology

Volumn 28, Issue 11, 1998, Pages 661-665

  Kuriyama, Manabu ^a   Kawada, Yukimichi ^a   Arai, Yoichi ^b   Maeda, Hiroshi ^b   Egawa, Shin ^c   Koshiba, Ken ^c   Imai, Kyoichi ^d   Yamanaka, Hidetoshi ^e  

^a GIFU UNIVERSITY   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Atagawa Hot Spa Hospital   (Japan)

^e GUNMA UNIVERSITY   (Japan)

Author keywords

Fit ratio of PSA; Prostate cancer; PSA gray zone; Screening PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD; HUMAN; MALE; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0032214821     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.11.661     Document Type: Article

References (14)

1. Oesterling JE Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
2. Kuriyama M. Prostate-specific antigen as a tumor marker in prostate cancer. Int J Urol 1994;1:99-113.
3. Oesterling JE, Jacobsen SJ, Klee GG, Petterson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate-specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-5.
4. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
5. Higashihara E, Nutahara K, Kojima M, Okegawa T, Miura I, Miyata A, et al. Significance of serum free prostate specific antigen in the screening of prostate cancer. J Urol 1996;156:1964-8.
6. Egawa S, Soh S, Ohori M, Uchida T, Gohji K, Fujii A, et al. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer 1997;79:90-8.
7. Tanaka H, Murakami S, Igarashi T, Abe T, Suzuki K, Sekita N, et al. Free/total PSA ratio of prostate-specific antigen (PSA) for prostate cancer detection in patients with gray zone PSA level. Hinyokika Kiyo 1997;43:855-60 (in Japanese).
8. Imai K, Yamanaka H, Kubota H. Determination of normal reference values using IMMULYZE HS-PSA and IMMULYZE PSA on mass screening for prostate cancer. Hinyoki Geka 1998;11:299-306 (in Japanese).
9. Semjonow A, Oberpenning F, Brandt B, Zeckel C, Brandau W, Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 1996;48(6A):10-4.
10. Dunn OJ. Multiple compansons using ranks. Technometrics 1964;6:241-52.
11. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36
12. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
13. Catolana WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentration of 2.6-4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.
14. Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B, et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996;42:1026-33.